16499-56-2

Basic information

• Product Name: 6-FLUOROQUINAZOLIN-4-ONE
• Synonyms: 6-FLUOROQUINAZOLIN-4-ONE;6-fluoroquinazolin-4(3H)-one;6-Fluoro-4-hydroxyquinazoline;6-Fluoroquinazolin-4-ol;4(3H)-Quinazolinone, 6-fluoro-;6-Fluoro-3H-quinazolin-4-one;6-fluoro-1H-quinazolin-4-one
• CAS NO: 16499-56-2
• Molecular Formula: C₈H₅FN₂O
• Molecular Weight: 164.14
• Product Categories: pharmacetical
• Mol File: 16499-56-2.mol
• Article Data: 39

Chemical Properties

• Melting Point: 250 °C
• Boiling Point: 318.266 °C at 760 mmHg
• Flash Point: 146.282 °C
• Appearance: /
• Density: 1.442 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.642
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.28±0.20(Predicted)
• CAS DataBase Reference: 6-FLUOROQUINAZOLIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUOROQUINAZOLIN-4-ONE(16499-56-2)
• EPA Substance Registry System: 6-FLUOROQUINAZOLIN-4-ONE(16499-56-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 16499-56-2(Hazardous Substances Data)

Usage

Description

6-Fluoroquinazolin-4-one, with the molecular formula C8H5FN2O, is a chemical compound that belongs to the quinazolin-4-one family. It is characterized by the presence of a fluorine atom in place of a hydrogen atom within the quinazolin-4-one ring. This unique structure and reactivity make 6-Fluoroquinazolin-4-one a valuable compound in medicinal chemistry and pharmaceutical research, where its bioactivity and pharmacological properties are extensively studied.

Uses

Used in Medicinal Chemistry:
6-Fluoroquinazolin-4-one is used as a building block in the synthesis of other organic compounds for medicinal chemistry. Its unique structure allows for the creation of new molecules with desired properties, making it a valuable tool in the development of new drugs.
Used in Pharmaceutical Research:
In pharmaceutical research, 6-Fluoroquinazolin-4-one is utilized as a compound with potential bioactivity and pharmacological properties. Its study aids in understanding its potential applications in the treatment of various diseases and conditions.
Used in Drug Development:
6-Fluoroquinazolin-4-one is used as a precursor in the development of new drugs. Its unique reactivity and structure enable the modification of its properties, which can lead to the creation of effective therapeutic agents.
Used in Material Science:
Although not explicitly mentioned in the provided materials, given its unique structure and reactivity, 6-Fluoroquinazolin-4-one could potentially be used in material science for the development of new materials with specific properties, such as in the creation of advanced polymers or other synthetic materials with tailored characteristics for various applications.

InChI:InChI=1/C8H5FN2O/c9-5-1-2-7-6(3-5)8(12)11-4-10-7/h1-4H,(H,10,11,12)

Upstream product

• 134792-45-3 6-fluoro-2H-benzo[e][1,3]oxazine-2,4(3H)-dione 
• 446-08-2 2-amino-5-fluorobenzoic acid 
• 3473-63-0 formamidine acetic acid 
• 77287-34-4 formamide 
• 64-18-6 formic acid 
• 149-73-5 trimethyl orthoformate 
• 122-51-0 orthoformic acid triethyl ester 
• 67-56-1 methanol 
• 61272-77-3 2-cyano-4-fluoroaniline 
• 63069-49-8 2-amino-5-fluorobenzamide 
• 67-68-5 dimethyl sulfoxide 
• 319-24-4 2-amino-5-fluoro-benzoic acid methyl ester 
• 6313-33-3 formamidine hydrochloride 

Downstream Products

• 1262888-20-9 N-(4-chlorobenzyl)-6-fluoroquinazoline-4-amine 
• 1262888-28-7 N-(4-fluorobenzyl)-6-fluoroquinazoline-4-amine 

Relevant articles and documents

Design, Synthesis, Crystal Structure, and Antimicrobial Evaluation of 6-Fluoroquinazolinylpiperidinyl-Containing 1,2,4-Triazole Mannich Base Derivatives against Phytopathogenic Bacteria and Fungi

A total of 20 1,2,4-triazole Mannich base derivatives bearing the 6-fluoroquinazolinylpiperidinyl moiety were designed, synthesized, and evaluated as antimicrobial agents against phytopathogenic bacteria and fungi according to the molecular hybridization strategy. Of note, the structure of target compound 4h was clearly confirmed through single-crystal X-ray diffraction analysis. The turbidimetric assays indicated that some compounds exhibited excellent antibacterial efficacies in vitro against Xanthomonas oryzae pv. oryzae (Xoo). For example, compounds 4c, 4f, 4j, and 7j had EC50 values of 23.6, 18.8, 23.4, and 24.3 μg/mL, respectively, which were far superior to that of agrobactericide bismerthiazol (EC50 = 92.4 μg/mL). In particular, compound 4f demonstrated a potent anti-Xoo activity approximately five times more active than that of bismerthiazol. Moreover, in vivo assays showed the excellent protective and curative activities of compound 4f against rice bacterial blight, having the potential as an alternative bactericide for controlling Xoo. The structure-activity relationship analysis showed a good pesticide-likeness concerning compound 4f, following Tice's criteria. The anti-Xoo mechanism of compound 4f was preliminarily explored by scanning electron microscopy measurements in living bacteria. Finally, several compounds also exhibited good antifungal activities in vitro against Gibberella zeae at 50 μg/mL. In short, the presented work showed the potential of 6-fluoroquinazolinylpiperidinyl-containing 1,2,4-triazole Mannich base derivatives as effective bactericides for controlling Xoo.

Synthesis and antifungal activity of novel s-substituted 6-fluoro-4-alkyl(aryl)thioquinazoline derivatives

6-Fluoro-4-quinazolinol is prepared by the cyclization reaction of 2-amino-5-fluorobenzoic acid and formamide. The resulting thiol obtained by treatment of hydroxyl group with phosphorus (V) sulfide is converted under phase transfer condition to 4-substit

Design, synthesis, and evaluation of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides as antitumor agents

In our continuing search for novel small-molecule anticancer agents, we designed and synthesized a series of novel (E)-N'-(3-allyl-2-hydroxy)benzylidene-2-(4-oxoquinazolin-3(4H)-yl)acetohydrazides (5), focusing on the modification of substitution in the quinazolin-4(3H)-one moiety. The biological evaluation showed that all 13 designed and synthesized compounds displayed significant cytotoxicity against three human cancer cell lines (SW620, colon cancer; PC-3, prostate cancer; NCI-H23, lung cancer). The most potent compound 5l displayed cytotoxicity up to 213-fold more potent than 5-fluorouracil and 87-fold more potent than PAC-1, the first procaspase-activating compound. Structure–activity relationship analysis revealed that substitution of either electron-withdrawing or electron-releasing groups at positions 6 or 7 on the quinazolin-4(3H)-4-one moiety increased the cytotoxicity of the compounds, but substitution at position 6 seemed to be more favorable. In the caspase activation assay, compound 5l was found to activate the caspase activity by 291% in comparison to PAC-1, which was used as a control. Further docking simulation also revealed that this compound may be a potent allosteric inhibitor of procaspase-3 through chelation of the inhibitory zinc ion. Physicochemical and ADMET calculations for 5l provided useful information of its suitable absorption profile and some toxicological effects that need further optimization to be developed as a promising anticancer agent.

Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities

A series of quinazolinyl-containing benzamide derivatives were designed, synthesized and evaluated for their in vitro histone deacetylase 1 (HDAC1) inhibitory activities. Compounds 11a surpassed the known class I selective HDAC inhibitor MS-275 in both HDAC1 enzymatic inhibitory activity and cellular anti-proliferative activity against a selected set of cancer cell types (Hut78, K562, Hep3B and HCT116 cells) with no observed effects on human normal cells. In particular, compound 11a inhibited HDAC1 over the other tested HDACs isoforms (HDAC2, HDAC6 and HDAC8) with acceptable safety profiles. Moreover, compound 11a displayed favorable oral pharmacokinetic properties and showed significant antitumor activity in the A549 tumor xenograft model in vivo.